22245-98-3

Basic information

• Product Name: 6-HYDROXY-3,4-DIHYDRO-1(2H)-ISOQUINOLINONE
• Synonyms: 6-HYDROXY-3,4-DIHYDRO-1(2H)-ISOQUINOLINONE;6-Hydroxy-3,4-dihydro-1(2H)-isoquinolinone ,97%;6-hydroxy-1,2,3,4-tetrahydroisoquinolin-1-one;1(2H)-Isoquinolinone,3,4-dihydro-6-hydroxy-;3,4-Dihydro-6-hydroxyisoquinolin-1(2H)-one
• CAS NO: 22245-98-3
• Molecular Formula: C₉H₉NO₂
• Molecular Weight: 163.18
• Mol File: 22245-98-3.mol
• Article Data: 21

Chemical Properties

• Boiling Point: 503.151 °C at 760 mmHg
• Flash Point: 258.097 °C
• Appearance: /
• Density: 1.283 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.604
• CAS DataBase Reference: 6-HYDROXY-3,4-DIHYDRO-1(2H)-ISOQUINOLINONE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-HYDROXY-3,4-DIHYDRO-1(2H)-ISOQUINOLINONE(22245-98-3)
• EPA Substance Registry System: 6-HYDROXY-3,4-DIHYDRO-1(2H)-ISOQUINOLINONE(22245-98-3)

Safety Data

• Hazardous Substances Data: 22245-98-3(Hazardous Substances Data)

Usage

General Description

6-HYDROXY-3,4-DIHYDRO-1(2H)-ISOQUINOLINONE is a chemical compound with the molecular formula C9H9NO2. It is a derivative of isoquinolinone and is found in the roots of plants from the family Papaveraceae. 6-HYDROXY-3,4-DIHYDRO-1(2H)-ISOQUINOLINONE has been studied for its potential pharmacological properties, including its ability to act as an antioxidant and anti-inflammatory agent. It has also been investigated for its potential in treating neurological disorders and as a therapeutic agent for cardiovascular diseases. Additionally, 6-HYDROXY-3,4-DIHYDRO-1(2H)-ISOQUINOLINONE may have potential applications in the design and development of new pharmaceutical drugs. Further research is needed to fully understand the effects and potential uses of this compound.

InChI:InChI=1/C9H9NO2/c11-7-1-2-8-6(5-7)3-4-10-9(8)12/h1-2,5,11H,3-4H2,(H,10,12)

Upstream product

• 22246-12-4 6-methoxy-1,2,3,4-tetrahydro-1-oxoisoquinoline 
• 3470-49-3 5-hydroxy-2,3-dihydro-1H-indene-1-one 
• 33543-63-4 ethyl-N-<2-(3-methoxyphenyl)ethyl>-carbamate 
• 2039-67-0 2-(3-methoxyphenyl)-1-ethanamine 
• 5111-70-6 5-methoxy-1-indanone 
• 76-03-9 trichloroacetic acid 
• 110192-21-7 N-(methoxycarbonyl)-2-(3'-methoxyphenyl)ethylamine 
• 588-05-6 m-tyramine 

Downstream Products

• 164147-66-4 6-(benzyloxy)-3,4-dihydroisoquinolin-1(2H)-one 
• 164147-67-5 (6-Benzyloxy-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl)-acetic acid tert-butyl ester 
• 190604-20-7 6-[(4-cyanophenyl)-(E)-ethenyl]-3,4-dihydro-1-oxo-2(1H)-isoquinolineacetic acid 1,1-dimethylethyl ester 
• 164147-72-2 [6-(4-Cyano-phenylethynyl)-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl]-acetic acid tert-butyl ester 
• 1027969-04-5 [6-(3-Aminomethyl-benzyloxy)-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl]-acetic acid tert-butyl ester 
• 164147-69-7 [6-(4-Cyano-benzyloxy)-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl]-acetic acid tert-butyl ester 
• 164148-48-5 [6-(4-Aminomethyl-benzyloxy)-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl]-acetic acid tert-butyl ester 
• 190604-17-2 {6-[2-(4-Cyano-phenyl)-ethoxy]-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl}-acetic acid tert-butyl ester 
• 1027422-55-4 {1-Oxo-6-[(E)-2-(4-thiocarbamoyl-phenyl)-vinyl]-3,4-dihydro-1H-isoquinolin-2-yl}-acetic acid tert-butyl ester 
• 1026228-40-9 {6-[(E)-2-(4-Carbamimidoyl-phenyl)-vinyl]-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl}-acetic acid tert-butyl ester 
• 164147-78-8 (6-Benzyloxycarbonylamino-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl)-acetic acid tert-butyl ester 
• 164147-70-0 [6-(4-Carbamimidoyl-benzyloxy)-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl]-acetic acid tert-butyl ester 
• 164147-80-2 [6-(4-Cyano-benzoylamino)-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl]-acetic acid tert-butyl ester 
• 1026339-13-8 [1-Oxo-6-(4-thiocarbamoyl-phenylethynyl)-3,4-dihydro-1H-isoquinolin-2-yl]-acetic acid tert-butyl ester 

Relevant articles and documents

1-[2-(1-Cyclobutylpiperidin-4-yloxy)-6,7-dihydro-4H-thiazolo[5,4-c]pyridin-5-yl]propan-1-one: a Histamine H3 Receptor Inverse Agonist with Efficacy in Animal Models of Cognition

A series of chemical optimizations, which was guided by in vitro affinity at histamine H3 receptor (H3R), modulation of lipophilicity, ADME properties and preclinical efficacy resulted in the identification of 1-[2-(1-cyclobutylpiperidin-4-yloxy)-6,7-dihydro-4H-thiazolo[5,4-c]pyridin-5-yl]propan-1-one (45 e) as a potent and selective (Ki=4.0 nM) H3R inverse agonist. Dipsogenia induced by (R)-α-methylhistamine was dose dependently antagonized by 45 e, confirming its functional antagonism at H3R. It is devoid of hERG and phospholipidosis issues. Compound 45 e has adequate oral exposures and favorable half-life in both rats and dogs. It has demonstrated high receptor occupancy (ED80=0.22 mg/kg) and robust efficacy in object recognition task and, dose dependently increased acetylcholine levels in brain. The sub-therapeutic doses of 45 e in combination with donepezil significantly increased acetylcholine levels. The potent affinity, selectivity, in vivo efficacy and drug like properties together with safety, warrant for further development of this molecule for potential treatment of cognitive disorders associated with Alzheimer's disease.

FLUOROALLYLAMINE DERIVATIVE AND USE THEREOF

The present invention relates to a fluoroallylamine derivative and use thereof. In particular, the present invention relates to a compound as shown in Formula I, a prodrug, an isomer, an isotope-labeled compound, a solvate or a pharmaceutically acceptable salt thereof, which has VAP-1/SSAO inhibitory activity, and can be used for treating a disease associated with VAP-1/SSAO overactivity.

Quinoline and Isoquinoline Based HDAC Inhibitors and Methods of Use Thereof

The present invention relates to methods of modulating activity of histone deacetylases (HDACs). The present invention also relates to methods of treating HDAC-associated diseases including, but not limited to, cancers, inflammatory disorders, and neurode